KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Total Current Liabilities (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Total Current Liabilities for 6 consecutive years, with $155.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Current Liabilities changed N/A year-over-year to $155.1 million, compared with a TTM value of $155.1 million through Sep 2025, changed N/A, and an annual FY2024 reading of $187.5 million, changed N/A over the prior year.
  • Total Current Liabilities was $155.1 million for Q3 2025 at Recursion Pharmaceuticals, down from $164.0 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $187.5 million in Q4 2024 and bottomed at $26.9 million in Q1 2021.
  • Average Total Current Liabilities over 5 years is $97.6 million, with a median of $94.4 million recorded in 2022.
  • The sharpest move saw Total Current Liabilities surged 227.19% in 2022, then increased 7.52% in 2023.
  • Year by year, Total Current Liabilities stood at $46.7 million in 2021, then skyrocketed by 114.89% to $100.3 million in 2022, then grew by 13.66% to $114.0 million in 2023, then soared by 64.51% to $187.5 million in 2024, then decreased by 17.27% to $155.1 million in 2025.
  • Business Quant data shows Total Current Liabilities for RXRX at $155.1 million in Q3 2025, $164.0 million in Q2 2025, and $142.0 million in Q1 2025.